Fredag 14 Mars | 11:56:49 Europe / Stockholm

Kalender

Est. tid*
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-04-07 N/A X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 N/A Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.
2025-03-06 08:30:00

Aiforia Technologies Plc, Press Release, March 6, 2025 at 09:30 a.m. EET

Aiforia closes a deal with a regional health authority of Sardinia in Italy 

The regional health authority of Sardinia in Italy has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics. This collaboration involves utilizing Aiforia's clinical AI solutions to analyze biopsies from breast and prostate cancer patients.

The two-year contract is part of a procurement of seven hospitals in the region, which aims to improve the diagnostic workflow of the region's pathology laboratories. The provider in the deal is a GPI S.p.A. lead consortium, and Aiforia is one of their subcontractors.

“We are excited to announce yet another clinical deal in Italy. This partnership marks an important achievement in our company's European expansion and strengthens our dedication to providing innovative solutions and exceptional value to our customers. We are also delighted that, together with our partners, we can again provide a solution that helps the customer to enhance their diagnostic workflows,” says Jukka Tapaninen, CEO of Aiforia.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

 

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com